This Article Full Text Full Text (PDF) All Versions of this Article: 26/9/2103    most recent 01.ATV.0000235724.11299.76v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winter, P. M. Articles by Lanza, G. M. Search for Related Content PubMed PubMed Citation Articles by Winter, P. M. Articles by Lanza, G. M.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2103.)
© 2006 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Endothelial ß₃ Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis

Patrick M. Winter; Anne M. Neubauer; Shelton D. Caruthers; Thomas D. Harris; J. David Robertson; Todd A. Williams; Anne H. Schmieder; Grace Hu; John S. Allen; Elizabeth K. Lacy; Huiying Zhang; Samuel A. Wickline; Gregory M. Lanza

From the Department of Medicine (P.M.W., A.M.N., S.D.C., T.A.W., A.H.S., G.H., J.S.A., E.K.L., H.Z., S.A.W., G.M.L.), Cardiovascular Magnetic Resonance Laboratories, Washington University School of Medicine, St Louis, Mo; Philips Medical Systems (S.D.C.), Cleveland, Ohio; Bristol-Myers Squibb Medical Imaging (T.D.H.), Billerica, Mass; and the University of Missouri Research Reactor (J.D.R.), Columbia.

Correspondence to Patrick M. Winter, PhD, Department of Medicine, Washington University, 660 S Euclid Ave, Campus Box 8086, St Louis, MO 63110. E-mail patrick{at}cvu.wustl.edu; or Gregory M. Lanza, MD, PhD. E-mail greg@cvu.wustl.edu

Objective— Angiogenic expansion of the vasa vasorum is a well-known feature of progressive atherosclerosis, suggesting that antiangiogenic therapies may stabilize or regress plaques. ß₃ Integrin–targeted paramagnetic nanoparticles were prepared for noninvasive assessment of angiogenesis in early atherosclerosis, for site-specific delivery of antiangiogenic drug, and for quantitative follow-up of response.

Methods and Results— Expression of ß₃ integrin by vasa vasorum was imaged at 1.5 T in cholesterol-fed rabbit aortas using integrin-targeted paramagnetic nanoparticles that incorporated fumagillin at 0 µg/kg or 30 µg/kg. Both formulations produced similar MRI signal enhancement (16.7%±1.1%) when integrated across all aortic slices from the renal arteries to the diaphragm. Seven days after this single treatment, integrin-targeted paramagnetic nanoparticles were readministered and showed decreased MRI enhancement among fumagillin-treated rabbits (2.9%±1.6%) but not in untreated rabbits (18.1%±2.1%). In a third group of rabbits, nontargeted fumagillin nanoparticles did not alter vascular ß₃-integrin expression (12.4%±0.9%; P>0.05) versus the no-drug control. In a second study focused on microscopic changes, fewer microvessels in the fumagillin-treated rabbit aorta were counted compared with control rabbits.

Conclusions— This study illustrates the potential of combined molecular imaging and drug delivery with targeted nanoparticles to noninvasively define atherosclerotic burden, to deliver effective targeted drug at a fraction of previous levels, and to quantify local response to treatment.

ß₃-Targeted paramagnetic nanoparticles were used to detect early atherosclerosis, to deliver an antiangiogenic drug, and to quantitatively assess neovascular response. This dual molecular imaging drug-delivery agent suggests that nanomedicine may provide an opportunity to intervene in the clinical progression of atherosclerosis, particularly in asymptomatic patients.

Key Words: magnetic resonance imaging • atherosclerosis • molecular imaging • angiogenesis • nanoparticles • fumagillin

This article has been cited by other articles:

				H.-f. Zhou, H. W. Chan, S. A. Wickline, G. M. Lanza, and C. T. N. Pham {alpha}v{beta}3-Targeted nanotherapy suppresses inflammatory arthritis in mice FASEB J, September 1, 2009; 23(9): 2978 - 2985. [Abstract] [Full Text] [PDF]

				D. P. Cormode, T. Skajaa, Z. A. Fayad, and W. J.M. Mulder Nanotechnology in Medical Imaging: Probe Design and Applications Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 992 - 1000. [Abstract] [Full Text] [PDF]

				R. P. Choudhury and E. A. Fisher Molecular Imaging in Atherosclerosis, Thrombosis, and Vascular Inflammation Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 983 - 991. [Abstract] [Full Text] [PDF]

				I. Laitinen, A. Saraste, E. Weidl, T. Poethko, A. W. Weber, S. G. Nekolla, P. Leppanen, S. Yla-Herttuala, G. Holzlwimmer, A. Walch, et al. Evaluation of {alpha}v{beta}3 Integrin-Targeted Positron Emission Tomography Tracer 18F-Galacto-RGD for Imaging of Vascular Inflammation in Atherosclerotic Mice Circ Cardiovasc Imaging, July 1, 2009; 2(4): 331 - 338. [Abstract] [Full Text] [PDF]

				J. H.F. Rudd, F. Hyafil, and Z. A. Fayad Inflammation Imaging in Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1009 - 1016. [Abstract] [Full Text] [PDF]

				F. A. Jaffer, P. Libby, and R. Weissleder Optical and Multimodality Molecular Imaging: Insights Into Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1017 - 1024. [Abstract] [Full Text] [PDF]

				M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al. Multimodality Cardiovascular Molecular Imaging, Part II Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70. [Full Text] [PDF]

				A. H. Schmieder, S. D. Caruthers, H. Zhang, T. A. Williams, J. D. Robertson, S. A. Wickline, and G. M. Lanza Three-dimensional MR mapping of angiogenesis with {alpha}5{beta}1({alpha}{nu}{beta}3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model FASEB J, December 1, 2008; 22(12): 4179 - 4189. [Abstract] [Full Text] [PDF]

				I. J. Sarembock From Systemic Shotgun to Site-Specific Nanoparticle-Targeted Delivery: A New Paradigm for Drug Delivery Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1879 - 1881. [Full Text] [PDF]

				P. M. Winter, S. D. Caruthers, H. Zhang, T. A. Williams, S. A. Wickline, and G. M. Lanza Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J. Am. Coll. Cardiol. Img., September 1, 2008; 1(5): 624 - 634. [Abstract] [Full Text] [PDF]

				E. Arbustini and F. I. Gambarin Theranostic strategy against plaque angiogenesis. J. Am. Coll. Cardiol. Img., September 1, 2008; 1(5): 635 - 637. [Full Text] [PDF]

				W. J.M. Mulder and Z. A. Fayad Nanomedicine Captures Cardiovascular Disease Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 801 - 802. [Full Text] [PDF]

				F. A. Jaffer, P. Libby, and R. Weissleder Molecular Imaging of Cardiovascular Disease Circulation, August 28, 2007; 116(9): 1052 - 1061. [Full Text] [PDF]

				F. D. Kolodgie, J. Narula, C. Yuan, A. P. Burke, A. V. Finn, and R. Virmani Elimination of Neoangiogenesis for Plaque Stabilization: Is There a Role for Local Drug Therapy? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2093 - 2101. [Abstract] [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1740 - 1749. [Full Text] [PDF]

				D. E. Sosnovik, M. Nahrendorf, and R. Weissleder Molecular Magnetic Resonance Imaging in Cardiovascular Medicine Circulation, April 17, 2007; 115(15): 2076 - 2086. [Full Text] [PDF]